51 results on '"Travis, Simon P."'
Search Results
2. 629 A SINGLE-CELL THERAPEUTIC ATLAS OF ANTI-TUMOUR NECROSIS FACTOR THERAPY IN INFLAMMATORY BOWEL DISEASE
3. Biallelic TLR4 deficiency in humans
4. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
5. Sa1626: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF ULCERATIVE COLITIS SYMPTOMS ON DAILY LIFE
6. 978: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF MODERATELY-TO-SEVERELY-ACTIVE ULCERATIVE COLITIS ON SEXUAL ACTIVITY
7. Sa1624: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: BURDEN AND IMPACT OF BOWEL URGENCY ON PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
8. 584: VEDOLIZUMAB INTRAVENOUS IS EFFECTIVE ACROSS MULTIPLE TREATMENT TARGETS IN CHRONIC POUCHITIS: RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EARNEST TRIAL
9. ID: 3526290 ARTIFICIAL INTELLIGENCE (AI) IN ENDOSCOPY - DEEP LEARNING FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY UNDER MULTIPLE SCORING SYSTEMS
10. ID: 3527087 PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING
11. 106 RANDOMIZED CLINICAL TRIAL: EXCLUSIVE ENTERAL NUTRITION VERSUS STANDARD OF CARE FOR ACUTE SEVERE ULCERATIVE COLITIS
12. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease
13. Su1931 PATIENT-REPORTED SYMPTOMS OVER A PERIOD OF 14 DAYS RELIABLY PREDICT ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS (UC)
14. Tu1875 IMPACT OF DISEASE DURATION ON TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS
15. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY
16. Su1921 THE ESCALATION OF THERAPY OR INTERVENTION (ETI) CALCULATOR FOR ULCERATIVE COLITIS - DOES IT HAVE THE POTENTIAL TO HELP OUTPATIENT CAPACITY MEET DEMAND?
17. Su1938 PATIENT REPORTED OUTCOMES: THE ICHOM STANDARD SET FOR IBD IN REAL LIFE PRACTICE HELPS QUANTIFY DEFICITS IN CURRENT CARE
18. Su1925 EARLY PREDICTION OF OUTCOME IN ACUTE SEVERE ULCERATIVE COLITIS (ASC) - COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES AT PRESENTATION, WITH DAY 3 CRITERIA
19. Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data
20. Mo1891 – Post-Marketing Safety Experience of Vedolizumab in Patients Receiving Concomitant Treatment with Other Biologics
21. Sa1801 – Emerging IBD Demographics in South Asia and Middle East : A Pilot Study from the IBD Emerging Nations' Consortium (IBDENC)
22. Tu1721 – Maintenance of Efficacy Following Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission
23. Tu1792 – Gut Microbiome Diversity in Acute Severe Colitis is Distinct from Mild to Moderate Ulcerative Colitis
24. Tu1714 – Impact of Upadacitinib on the General Clinical Condition of Patients with Crohn's Disease (CD): Data from the Randomised Celest Study
25. Mo1878 – Lymphocyte Activation Gene (LAG)-3 on T Cells is a Potential Therapeutic Target in Ulcerative Colitis
26. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm
27. Su1795 - Developing an Index that Predicts Escalation of Therapy at an Outpatient Appointment in Patients with Known Ulcerative Colitis (UC)
28. 1003 - New Faecal Calprotectin Cut-Off Points for Remission and Active Disease Defined by Uceis and Nancy Indices in Ulcerative Colitis
29. Sa1775 - A Novel Phase 1 Trial Design to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Top1288, a Narrow Spectrum Kinase Inhibitor, Delivered Topically to the Colon via Oral Administration
30. Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm
31. Sa1703 - Post-Marketing Safety Experience of Vedolizumab in Older Patients with Inflammatory Bowel Disease
32. Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
33. Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial
34. Correlation between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices
35. Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm
36. Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections
37. Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
38. Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience
39. Treat to Target: Recommendations in Ulcerative Colitis (UC) in Practice: Clinician Perceptions and Potential Barriers
40. Zero Diagnostic Yield of Dysplasia in Polyp Adjacent Biopsies for Patients with Inflammatory Bowel Disease
41. Predictors of Long-Term Outcomes in Patients with Acute Severe Ulcerative Colitis: A Northern Indian Cohort Study
42. Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
43. Defining Patient-Centered Outcomes for IBD and an International, Cross-Disciplinary Consensus
44. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial
45. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial
46. Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis
47. The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease
48. Unexplained gastrointestinal symptoms: Think mitochondrial disease
49. The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis
50. Comparison between prospective and retrospective evaluation of Crohn's disease activity index
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.